<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The protective properties of PY 108-068 against ischemic disturbances in the brain were investigated in vitro and in vivo </plain></SENT>
<SENT sid="1" pm="."><plain>The calcium antagonistic effects were demonstrated on isolated, calcium-loaded arterial rings of feline cerebral arteries </plain></SENT>
<SENT sid="2" pm="."><plain>Determination of brain tissue oxygenation with pO2 microelectrodes showed that PY 108-068 improved oxygen supply in the cortex of cats subjected to epicerebral <z:mp ids='MP_0006134'>arterial occlusion</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>In a model of <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> induced by autologous blood superfusion, PY 108-068 reversed the spastic state of cortical microvessels </plain></SENT>
<SENT sid="4" pm="."><plain>In a <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> model (microsphere embolization in rats) PY 108-068 led to a significant reduction in mortality and in the severity of neurological symptoms, whereby the peroral efficacy of the drug could be demonstrated </plain></SENT>
<SENT sid="5" pm="."><plain>The efficacy of PY 108-068 in a variety of ischemic insults makes this drug a promising aid in the treatment of <z:hpo ids='HP_0001297'>cerebrovascular accidents</z:hpo> </plain></SENT>
</text></document>